These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 28988277)

  • 21. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.
    Schlender JF; Meyer M; Thelen K; Krauss M; Willmann S; Eissing T; Jaehde U
    Clin Pharmacokinet; 2016 Dec; 55(12):1573-1589. PubMed ID: 27351180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantification of vorinostat and its main metabolites in plasma and intracellular vorinostat in PBMCs by liquid chromatography coupled to tandem mass spectrometry and its relation to histone deacetylase activity in human blood.
    Liu L; Detering JC; Milde T; Haefeli WE; Witt O; Burhenne J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Aug; 964():212-21. PubMed ID: 24636840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
    Hiriyan J; Shivarudraiah P; Gavara G; Annamalai P; Natesan S; Sambasivam G; Sukumaran SK
    Anticancer Res; 2015 Jan; 35(1):229-37. PubMed ID: 25550555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy.
    Kalanxhi E; Risberg K; Barua IS; Dueland S; Waagene S; Andersen SN; Pettersen SJ; Lindvall JM; Redalen KR; Flatmark K; Ree AH
    Cancer Res Treat; 2017 Apr; 49(2):374-386. PubMed ID: 27488871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans.
    Choi SW; Gatza E; Hou G; Sun Y; Whitfield J; Song Y; Oravecz-Wilson K; Tawara I; Dinarello CA; Reddy P
    Blood; 2015 Jan; 125(5):815-9. PubMed ID: 25428224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits.
    Wise LD; Turner KJ; Kerr JS
    Birth Defects Res B Dev Reprod Toxicol; 2007 Feb; 80(1):57-68. PubMed ID: 17294457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physiologically Based Pharmacokinetic Modeling of Oxycodone in Children to Support Pediatric Dosing Optimization.
    Zheng L; Xu M; Tang SW; Song HX; Jiang XH; Wang L
    Pharm Res; 2019 Oct; 36(12):171. PubMed ID: 31654287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
    Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
    Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat.
    Peer CJ; Hall OM; Sissung TM; Piekarz R; Balasubramaniam S; Bates SE; Figg WD
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):565-570. PubMed ID: 29951694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives.
    Srinivas NR
    Xenobiotica; 2017 Apr; 47(4):354-368. PubMed ID: 27226420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
    Duvic M; Dimopoulos M
    Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience.
    Bezecny P
    Med Oncol; 2014 Jun; 31(6):985. PubMed ID: 24838514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenomics and histone deacetylase inhibitors.
    Goey AK; Sissung TM; Peer CJ; Figg WD
    Pharmacogenomics; 2016 Nov; 17(16):1807-1815. PubMed ID: 27767376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
    Hrzenjak A; Moinfar F; Kremser ML; Strohmeier B; Petru E; Zatloukal K; Denk H
    Mol Cancer; 2010 Mar; 9():49. PubMed ID: 20202195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell Signaling Model Connects Vorinostat Pharmacokinetics and Tumor Growth Response in Multiple Myeloma Xenografts.
    Nanavati C; Ruszaj D; Mager DE
    CPT Pharmacometrics Syst Pharmacol; 2017 Nov; 6(11):756-764. PubMed ID: 29045072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
    Prebet T; Vey N
    Expert Opin Investig Drugs; 2011 Feb; 20(2):287-95. PubMed ID: 21192773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors.
    Fujiwara Y; Yamamoto N; Yamada Y; Yamada K; Otsuki T; Kanazu S; Iwasa T; Hardwick JS; Tamura T
    Cancer Sci; 2009 Sep; 100(9):1728-34. PubMed ID: 19575752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiologically Based Pharmacokinetic Modeling to Supplement Nilotinib Pharmacokinetics and Confirm Dose Selection in Pediatric Patients.
    Heimbach T; Lin W; Hourcade-Potelleret F; Tian X; Combes FP; Horvath N; He H
    J Pharm Sci; 2019 Jun; 108(6):2191-2198. PubMed ID: 30721710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
    Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
    Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.